Skip to content

Clinical evaluation and application of therapy drug monitor of 15 anti-tuberculosis drugs based on LC-MS technology

Clinical evaluation and application of therapy drug monitor of 15 anti-tuberculosis drugs based on LC-MS technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017733
Enrollment
Unknown
Registered
2018-08-11
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Gold Standard:TB culture from sputum
tandem&#32
spectrum

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Subjects are fully aware of the purpose, characters, methods and possible adverse reactions of the trial, volunteer as subjects and sign informed consent prior to any research procedure; 2) Subjects are more than 16 years; 3) have treated with anti-tuberculosis drugs for more than 7 days; 4) Patients have performed blood routine, urine routine and blood biochemical tests were collected on the day or the first 2 days of the specimen collection; 5) Patients have performed immune tests for blood transfusion 3 months before sample collection.

Exclusion criteria

Exclusion criteria: 1) Patients have token other drugs exclude anti-tuberculosis drugs; 2) Patients have poor adherence to medication; 3) Patients can not accurately give the information for drug name and the time for taking drugs.

Design outcomes

Primary

MeasureTime frame
Drug concentration;

Contacts

Public ContactLijun Zhang

Shanghai Public Health Clinical Center

zhanglijun1221@163.com+86 18916015028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026